ACT2_2D | R Documentation |
Kaplan-Meier digitized data from ACT2, figure 2D (PMID 26483047). A reported sample size of 233 for a primary endpoint of PFS-3mo in colorectal cancer.
ACT2_2D
A data frame of 67 observations and 3 variables:
time | event time (in months) | |
event | OS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (mut_b, mut_c) | |
Hagman H, Frödin J-E, Berglund Å, et al. A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial. Ann Oncol 2016; 27: 140–7.
summary(ACT2_2D)
kmplot(ACT2_2D)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.